Irska - angleščina - HPRA (Health Products Regulatory Authority)

generics (uk) limited - linezolid - solution for infusion - 2 mg/ml - linezolid

Belgija - angleščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - linezolid 2 mg/ml - solution for infusion - 2 mg/ml - linezolid 2 mg/ml - linezolid

Irska - angleščina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - linezolid - solution for infusion - 2 milligram(s)/millilitre - other antibacterials; linezolid

Združene države Amerike - angleščina - NLM (National Library of Medicine)

mylan institutional llc - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid injection is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)] . linezolid injection is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14)] . linezolid injection is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid injection has not been studied in the treatment of decubitus ulcers [see clinical studies (14)] . linezolid injection is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - linezolid - oral tablet - 600mg

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; ethylcellulose; silicon dioxide; povidone; microcrystalline cellulose; diethyl phthalate; purified talc - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

accord healthcare limited - linezolid (form iii) - film coated tablet - 600 milligram - linezolid - antibacterials for systemic use; other antibacterials - linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 600 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.